STOCK TITAN
  1. Home
  2. News
  3. NAOV

NanoVibronix, Inc. - NAOV STOCK NEWS

Welcome to our dedicated page for NanoVibronix news (Ticker: NAOV), a resource for investors and traders seeking the latest updates and insights on NanoVibronix stock.

NanoVibronix, Inc. (NASDAQ: NAOV) is a forward-thinking medical device company specializing in the development and commercialization of innovative products that leverage its proprietary low-intensity acoustic technology. Located in Elmsford, NY, with a subsidiary, NanoVibronix Ltd., based in Nesher, Israel, the company aims to revolutionize the medical field with cost-effective therapeutic ultrasound applications.

NanoVibronix's groundbreaking technology enables the creation of miniature transducers that transmit low-frequency, low-intensity ultrasound through flexible material surfaces. This unique feature is integral to a range of products designed for various medical applications, particularly those requiring noninvasive methods.

The company's flagship products include:

  • PainShield®: A patch-based device carrying FDA clearance, designed for pain management through the delivery of therapeutic ultrasound.
  • UroShield®: A device aimed at preventing biofilm formation and reducing urinary tract infections associated with catheter use.
  • WoundShield®: A device that promotes wound healing by transmitting low-frequency ultrasound waves to stimulate tissue regeneration.

NanoVibronix's products are designed for home use, enabling patients to receive therapy without the need for medical professionals. This approach not only enhances patient convenience but also reduces healthcare costs.

In addition to its direct-to-patient sales, NanoVibronix partners with distributors to expand its market reach. The company's recent achievements include securing FDA clearance for PainShield® and forming strategic partnerships to enhance product distribution.

Overall, NanoVibronix, Inc. stands out for its innovative approach to medical device technology, focusing on noninvasive solutions for pain management, biofilm prevention, and wound healing, making significant strides in improving patient outcomes.

News

NanoVibronix Issues Letter to Stockholders

Rhea-AI Summary
NanoVibronix, Inc. (NAOV) reported record revenues of $1.2 million in Q4 2023, alongside a loss of $702,000. The company focuses on developing and commercializing therapeutic devices like UroShield, PainShield, and WoundShield. Despite challenges in obtaining full approval for PainShield from CMS, NanoVibronix is seeing growth in domestic and international markets. The company is also conducting a RCT study with the University of Michigan to evaluate the efficacy of UroShield.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.87%
Tags
none
-
News

NanoVibronix Signs Agreement for Research and Development of Next Generation PainShield and UroShield

Rhea-AI Summary
NanoVibronix, Inc. (NAOV) partners with Veranex, Inc. to enhance UroShield and PainShield products, aiming to add therapeutic functionality and cut costs. The collaboration focuses on research and development services to innovate the next generation of devices, ensuring improved quality and reduced expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.43%
Tags
none
-
News

NanoVibronix Featured in Your Bladder Health Magazine

Rhea-AI Summary
NanoVibronix, Inc. (NASDAQ: NAOV) announced that its UroShield device is featured in Your Bladder Health Magazine for its effectiveness in preventing catheter-associated urinary tract infections (CAUTIs) and blockages. The article includes patient testimonials highlighting the positive impact on quality of life.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.92%
Tags
none
News

NanoVibronix Enters into Letter of Intent with APOGEPHA Arzneimittel GmbH to Explore European Distribution Opportunity

Rhea-AI Summary
NanoVibronix, Inc. (NASDAQ: NAOV) has entered into a non-binding letter of intent with APOGEPHA Arzneimittel GmbH to study the potential for APOGEPHA to distribute NanoVibronix’s UroShield product in Germany and other European markets. APOGEPHA, with a history of over 100 years, is a dedicated specialist in the field of urology. The goal is to better understand the feasibility of a distribution deal between both companies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
none
-
News

NanoVibronix Announces Agreement for Clinical Study of UroShield at the University of Michigan

Rhea-AI Summary
NanoVibronix, a medical device company listed on Nasdaq as NAOV, has signed a Research Agreement with the University of Michigan for a Randomized Control Trial study of UroShield. The company aims to gather additional clinical evidence to support an application to the FDA for permanent clearance of UroShield, a Portable Ultrasonic Therapeutic Device. The study will focus on the impact of UroShield on reducing urinary tract infections, catheter blockages, and pain, and improving the quality of life for nursing home residents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.87%
Tags
clinical trial
-
News

NanoVibronix Regains Nasdaq Compliance

Rhea-AI Summary
NanoVibronix, Inc. (NAOV) received official notice of compliance from The Nasdaq Stock Market LLC, meeting all criteria for continued listing, including the minimum stockholders' equity requirement of $2.5 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.16%
Tags
none
News

NanoVibronix Issues Letter to Shareholders

Rhea-AI Summary
NanoVibronix, Inc. (NASDAQ: NAOV) provided a review of Q3 2023 and recent business developments in a letter to shareholders from CEO Brian Murphy. The company recorded Q3 revenues of $458,000, with a loss from operations of $670,000. International progress in the UK and Australia/New Zealand, domestic sales expansion, product development, reimbursement efforts, and research updates were highlighted. The company aims to drive profitable growth by expanding distribution, licensing channels, and engaging consumers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.55%
Tags
none
-
News

NanoVibronix UroShield Products Available on NHS Drug Tariff Effective November 1

Rhea-AI Summary
NanoVibronix, Inc. (Nasdaq: NAOV) has received a stocking order from its U.K. distribution partner, Peak Medical Limited, in anticipation of increased demand for its UroShield actuators, which are now eligible for reimbursement on NHS Prescription Services’ Drug Tariff effective November 1. The company is ramping up production to meet the expected surge in demand, and the U.K. distribution partner is working to educate healthcare providers on the product's benefits and accept orders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.8%
Tags
none
-
News

NanoVibronix Gains Approval for Inclusion of UroShield Products in NHS Prescription Services’ Drug Tariff

Rhea-AI Summary
NanoVibronix receives reimbursement approval for UroShield actuators from NHS, allowing increased distribution to NHS patients. Contract with NHS Supply Chain extended for up to four years. Clinicians can prescribe UroShield beginning Nov 1, 2023. NHS will cover the cost. Positive impact on patient outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

NanoVibronix Announces Presentation of Positive Independent Testing Results of UroShield at ICS Annual Meeting

Rhea-AI Summary
Dr. Sandra Wilks to present findings from University of Southampton study on UroShield® at ICS 2023 conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.48%
Tags
none

FAQ

What is the current stock price of NanoVibronix (NAOV)?

The current stock price of NanoVibronix (NAOV) is $0.5413 as of December 23, 2024.

What is the market cap of NanoVibronix (NAOV)?

The market cap of NanoVibronix (NAOV) is approximately 2.2M.

What does NanoVibronix, Inc. specialize in?

NanoVibronix, Inc. specializes in creating medical devices that utilize low-intensity acoustic technology for pain management, biofilm prevention, and wound healing.

Where is NanoVibronix, Inc. located?

NanoVibronix, Inc. is located in Elmsford, NY, with a subsidiary in Nesher, Israel.

What are the primary products of NanoVibronix, Inc.?

The primary products are PainShield®, UroShield®, and WoundShield®, all of which use low-frequency, low-intensity ultrasound technology.

Is PainShield® FDA cleared?

Yes, the PainShield® device has received FDA clearance for pain management.

How do NanoVibronix's products work?

NanoVibronix's products use small, disposable transducers to transmit low-frequency, low-intensity ultrasound waves that help with tissue repair, pain reduction, and biofilm prevention.

Can NanoVibronix's devices be used at home?

Yes, NanoVibronix's devices are designed for home use, allowing patients to receive therapy without the aid of medical professionals.

Does NanoVibronix sell its products directly to patients?

Yes, the company sells its products directly to patients and also through distributor agreements.

What is the purpose of UroShield®?

UroShield® is designed to prevent biofilm formation on urinary catheters and reduce urinary tract infections.

What is the goal of WoundShield®?

WoundShield® aims to promote wound healing by transmitting low-frequency ultrasound waves to stimulate tissue regeneration.

What recent achievements has NanoVibronix made?

Recent achievements include FDA clearance for PainShield® and forming strategic partnerships to enhance product distribution.

Stock NAOV logo
NanoVibronix, Inc.

Nasdaq:NAOV

NAOV Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

NAOV Stock Data

2.15M
3.73M
0.69%
13.49%
4.68%
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States of America
TYLER